Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now

4 Stocks To Watch: EXAS, EXEL, NKTR, PBYI

Published 09/13/2016, 01:53 AM
Updated 07/09/2023, 06:31 AM

What a nice day on Wall Street on Monday, reversing from Friday’s huge drop. It had an opening gap down, Nasdaq 100 going from 4660, and running up to 4772, more than 115 points from top to bottom. The S&P 500 went from under 2120 to 2163, in nice, 45-degree angles, but I would be careful on Tuesday.

EXACT Sciences Corporation (NASDAQ:EXAS) looks really good, up 24 cents, or 1.27%, to 19.07, on 3 million shares traded. It had a nice reversal off support, 50-day, lateral price support, going from 17.61 to 19.08, closing just a penny off the high on a nice reversal day. I want to see if it gets up to the 20.29 zone. If it gets to 20-20.05 we’re going to have a run-on. I’m looking for wave five, which could take this stock up substantially.

Exelixis Inc (NASDAQ:EXEL) looks great, up 42 cents, or 3.5%, to 12.40, on 4.3 million shares traded. on Monday I love the way this stock came down, held at the double top, consolidated with reversal day off the low, and basically tested the bottom of the channel. It could be spiking up towards 15 pretty shortly. Keep an eye on this one. It has 6 days to cover.

Nektar Therapeutics (NASDAQ:NKTR) is one of my favorite biotech’s this year. It was up 66 cents, or 3.56%, on 1.2 million shares traded on Monday. I really like the way it’s acting, even though it pulled back, but it snapped back from 18.58 to 19.32, and closed at the highs for the day going away. The volume was solid but not strong. The next target is 21 1/2, and then 23.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Puma Biotechnlgy (NYSE:PBYI) had a breakout day on Monday, up 4.92, or 8.35%, to 63.82, on 806,616 shares traded on Monday. It popped, consolidated, had a breakout day 3 weeks ago, and popped and ran. I expect the same with Monday’s breakout. I’m looking for 72, and then 74 as targets.

Stocks on the long side included Acacia Communications Inc (NASDAQ:ACIA), Ambarella Inc (NASDAQ:AMBA), Accelerate Diagnostics Inc (NASDAQ:AXDX), Bluebird bio Inc (NASDAQ:BLUE), Clovis Oncology Inc (NASDAQ:CLVS), Conns Inc (NASDAQ:CONN), Clayton Williams Energy Inc (NYSE:CWEI), Exact Sciences Corporation (EXAS), Exelixis, Inc. (EXEL), Gigamon Inc (NYSE:GIMO), Himax Technologies Inc (NASDAQ:HIMX), Momo Inc (NASDAQ:MOMO), NII Holdings Inc (NASDAQ:NIHD), Nektar Therapeutics (NKTR), NeoPhotonics Corporation (NYSE:NPTN), Novavax Inc (NASDAQ:NVAX), Puma Biotechnology, Inc. (PBYI), Resolute Energy Corp (NYSE:REN), Reata Pharmaceuticals Inc (NASDAQ:RETA), Supernus Pharmaceuticals Inc (NASDAQ:SUPN), Vuzix Corp Cmn Stk (NASDAQ:VUZI), Wynn Resorts Limited (NASDAQ:WYNN), and Xencor Inc (NASDAQ:XNCR).

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.